How the Wegovy steps work — and why the pace matters

What are the actual steps, and how long does each one last?

The standard Wegovy titration runs in five stages. You begin at 0.25 mg per week for approximately four weeks. That dose serves one purpose: giving your digestive system time to adjust to a GLP-1 receptor agonist. Most people feel little at 0.25 mg beyond perhaps mild nausea in the first day or two after injecting.

From there the schedule moves to 0.5 mg, then 1.0 mg, then 1.7 mg, with roughly a month at each level. The 2.4 mg dose is the standard maintenance step, where most of the clinical weight-loss effect is observed. In the STEP 1 trial, published in the New England Journal of Medicine, participants at 2.4 mg averaged around 15% body-weight reduction over 68 weeks, a figure that reflects sustained treatment at the maintenance dose, not the early escalation phase.

If your prescriber determines you're a candidate for the newer 7.2 mg dose (which the MHRA approved as a dedicated single-dose pen in April 2026) the titration continues beyond 2.4 mg under the same principle: time at each level before moving up. The Wegovy overview page covers that approval in more detail. Your pen lives in the fridge between 2 and 8°C; many people keep it in the fridge door so it's easy to locate on injection day.

Why does Wegovy have steps rather than a single starting dose?

The short answer is tolerability. Semaglutide slows gastric emptying and acts on appetite-signalling pathways in the brain. At full maintenance doses the effects on the gut can be pronounced (nausea, loose stools, burping) and for most people those effects are manageable when the dose has been built up gradually. Start at 2.4 mg on day one and the same effects hit without warning.

The NHS medicines page for semaglutide confirms that nausea is the most commonly reported side effect, especially at the start of treatment or after a dose increase. The escalation schedule doesn't eliminate GI side effects, but it substantially reduces the chance they become severe enough to stop treatment altogether.

There is also a clinical rationale beyond comfort. Each step up allows the prescriber to assess how your body is responding. If 1.0 mg is already producing good results with good tolerability, there is no automatic obligation to push further, that conversation happens at clinical review. The semaglutide information page goes into the mechanism in more depth for anyone who wants it.

Can the steps be slowed, paused or adjusted?

Yes, and this is one of the most practically important things to know. The four-week intervals are a starting framework, not a rigid rule. If you reach the 1.0 mg step and nausea is making eating difficult, your prescriber can hold you at that dose for an extra four weeks (or longer) before the next step up. That kind of flexibility is written into how semaglutide is prescribed, not a workaround.

What you should not do is adjust the schedule yourself. Rushing a step up because you want faster results, or skipping a dose then trying to catch up, both carry risks: faster escalation amplifies GI side effects, and missed doses can disrupt the steady-state plasma levels that underpin efficacy. Missed-dose guidance is in your Patient Information Leaflet and should be discussed with your prescriber; neither the leaflet nor a content page should substitute for that conversation.

If you're considering switching from one dose of the injection to oral semaglutide, that's a clinical decision too. The individual step pages carry factual detail on each dose level. For context on what private treatment typically costs across the schedule, the Wegovy prices page lays out the honest picture.

What happens if the standard escalation doesn't suit me?

A small number of people find the standard four-week intervals too fast at specific steps, usually the move to 1.7 mg or 2.4 mg, where the dose change is relatively larger in percentage terms. Others tolerate the full schedule without much difficulty and reach maintenance without incident. Individual responses vary, and that variability is a reason the prescribing model exists.

The NICE recommendation for semaglutide (TA875) includes a review point at the maintenance dose: if less than 5% weight loss has occurred after six months on the highest tolerated dose, continuing treatment should be discussed with your prescriber. That review is built into responsible clinical practice, not something you need to raise yourself, though you can and should ask questions at any stage. Our clinical team at nume reviews every repeat order before it is dispensed; no prescription goes out without a fresh clinical look. If you'd like to talk through where you are in the schedule, the right place to start is a free consultation with our prescribers.